Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.770
-0.070 (-3.80%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Coherus Oncology Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Coherus Oncology stock have an average target of 5.51, with a low estimate of 1.05 and a high estimate of 10. The average target predicts an increase of 211.30% from the current stock price of 1.77.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 22, 2026.
Analyst Ratings
The average analyst rating for Coherus Oncology stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $10 | Buy | Initiates | $10 | +464.97% | Jan 22, 2026 |
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $4 | Hold → Strong Buy | Upgrades | $4 | +125.99% | Sep 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +295.48% | Apr 29, 2025 |
| UBS | UBS | Hold Maintains $1.5 → $1.05 | Hold | Maintains | $1.5 → $1.05 | -40.68% | Apr 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +295.48% | Mar 11, 2025 |
Financial Forecast
Revenue This Year
72.99M
from 42.17M
Increased by 73.08%
Revenue Next Year
95.57M
from 72.99M
Increased by 30.94%
EPS This Year
-0.93
from 1.43
EPS Next Year
-0.55
from -0.93
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 91.5M | 127.6M | ||||||
| Avg | 73.0M | 95.6M | ||||||
| Low | 62.9M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 116.9% | 74.8% | ||||||
| Avg | 73.1% | 30.9% | ||||||
| Low | 49.2% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.24 | - | ||||||
| Avg | -0.93 | -0.55 | ||||||
| Low | -1.34 | -1.13 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.